Little is known about whether 3,4-methylenedioxy-N-methamphetamine (MDMA) neurocognitive side effects improve with sustained abstinence. This study aimed to systematically review and synthesise the existing literature on the long-term neurocognitive side effects of recreational MDMA use after a minimum of 6 months of abstinence. We searched relevant databases utilising terms related to (1) MDMA and (2) neurocognition. A qualitative synthesis of study findings was organised with reference to the neurocognitive domains defined in the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM5). Fourteen articles met the inclusion criteria, assessing learning and memory (n = 8), executive function (n = 10), complex attention (n = 5), language (n = 2) and perceptual motor function (n = 1). Meta-analysis and assessment of bias were undertaken only for the domain of ‘learning and memory’ and included five studies. People with current and previous MDMA use had poorer learning and memory performance compared to people who were MDMA-naïve (Hedges’ g = −1.06 and −1.37, respectively); there was no significant difference between current and abstinent MDMA users (Hedges’ g = 0.03). A longer period of abstinence did not demonstrate greater improvements or recovery in learning and memory. There was limited evidence to conclude that MDMA use is associated with neurocognitive impairments in other domains. Overall, these conclusions are based on low-quality findings.
AguilarMAGarcia-PardoMPParrottAC (2020) Of mice and men on MDMA: A translational comparison of the neuropsychobiological effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’). Brain Research1727: 146556.
2.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th edn.
3.
BermanSO’NeillJFearsS, et al. (2008) Abuse of amphetamines and structural abnormalities in the brain. Annals of the New York Academy of Science1141: 195–220.
4.
BhattacharySPowellJH (2001) Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or ‘ecstasy’: Evidence for cognitive impairment. Psychological Medicine31(4): 647–658.
5.
BiezonskiDKMeyerJS (2011) The nature of 3, 4-methylenedioxymethamphetamine (MDMA)-induced serotonergic dysfunction: Evidence for and against the neurodegeneration hypothesis. Current Neuropharmacology9(1): 84–90.
BuchertRThomasiusRNebelingB, et al. (2003) Long-term effects of “ecstasy” use on serotonin transporters of the brain investigated by PET. Journal of Nuclear Medicine44(3): 375–384.
8.
BuchertRThomasiusRPetersenK, et al. (2006) Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. European Journal of Nuclear Medicine and Molecular Imaging33(2): 188–199.
9.
BuchertRThomasiusRWilkeF, et al. (2004) A voxel-based PET investigation of the long-term effects of “ecstasy” consumption on brain serotonin transporters. American Journal of Psychiatry161(7): 1181–1189.
10.
CadoniCPisanuASimolaN, et al. (2017) Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence. Neuropharmacology123: 385–394.
11.
CohenIVMakuntsTAbagyanR, et al. (2021) Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Scientific Reports11(1): 5997.
12.
ColadoMIGranadosRO’SheaE, et al. (1998) Role of hyperthermia in the protective action of clomethiazole against MDMA (‘ecstasy’)-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR. British Journal of Pharmacology124(3): 479–484.
13.
CostaGGolembiowskaK (2022) Neurotoxicity of MDMA: Main effects and mechanisms. Experimental Neurology347: 113894.
14.
CouchmanLFrinculescuASobreiraC, et al. (2019) Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 - A potential risk to users?Drug Testing and Analysis11(8): 1172–1182.
15.
CowanRLLyooIKSungSM, et al. (2003) Reduced cortical gray matter density in human MDMA (Ecstasy) users: A voxel-based morphometry study. Drug and Alcohol Dependence72(3): 225–235.
16.
CuyasEVerdejo-GarciaAFagundoAB, et al. (2011) The influence of genetic and environmental factors among MDMA users in cognitive performance. PLoS One6(11): e27206.
17.
DaumannJFischermanTHeekerenK, et al. (2004) Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: Evidence from an 18-month longitudinal functional magnetic resonance imaging study. Biological Psychiatry56(5): 349–355.
18.
De GregorioDAguilar-VallesAPrellerKH, et al. (2021) Hallucinogens in mental health: Preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. Journal of Neuroscience41(5): 891–900.
19.
Di IorioCRWatkinsTJDietrichMS, et al. (2012) Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users. Archives of General Psychiatry69(4): 399–409.
ErritzoeDFrokjaerVGHolstKK, et al. (2011) In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”) and hallucinogen users. Archives of General Psychiatry68(6): 562–576.
22.
FischerCHatzidimitriouGWlosJ, et al. (1995) Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Journal of Neuroscience15(8): 5476–5485.
23.
FlavelSCWhiteJMToddG (2012) Motor cortex and corticospinal excitability in humans with a history of illicit stimulant use. Journal of Applied Physiology113(9): 1486–1494.
24.
GoldingJFGroomeDHRycroftN, et al. (2007) Cognitive performance in light current users and ex-users of ecstasy (MDMA) and controls. The American Journal of Drug and Alcohol Abuse33(2): 301–307.
25.
Gouzoulis-MayfrankEDaumannJ (2006a) Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: How strong is the evidence for persistent brain damage?Addiction101(3): 348–361.
26.
Gouzoulis-MayfrankEDaumannJ (2006b) The confounding problem of polydrug use in recreational ecstasy/MDMA users: A brief overview. Journal of Psychopharmacology20(2): 188–193.
27.
Gouzoulis-MayfrankEDaumannJ (2009) Neurotoxicity of drugs of abuse - The case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues in Clinical Neuroscience11(3): 305–317.
28.
Gouzoulis-MayfrankEDaumannJSaßH (2002) Long-term neurotoxic brain damage in ecstasy (MDMA) users. A review of the literature. Der Nervenarzt73(5): 405–421.
29.
Gouzoulis-MayfrankEFischermannTRezkM, et al. (2005) Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use. Drug and Alcohol Dependence78(3): 317–323.
30.
GreenARCrossAJGoodwinGM (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ‘Ecstasy’). Psychopharmacology119(3): 247–260.
31.
GreenARMechanAOElliottJM, et al. (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacology Reviews55(3): 463–508.
32.
HansonKLLucianaM (2010) Neurocognitive impairments in MDMA and other drug users: MDMA alone may Not be a cognitive risk factor. Journal of Clinical and Experimental Neuropsychology32(4): 337–349.
33.
HansonKLLucianaMSullwoldK (2008) Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users. Drug and Alcohol Dependence96(1–2): 99–110.
34.
HatzidimitriouGMcCannUDRicaurteGA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: Factors influencing abnormal recovery. Journal of Neuroscience19(12): 5096–5107.
35.
JanouschCEggenbergerLSteinhoffA, et al. (2025) Words versus strands: Reliability and stability of concordance rates of self-reported and hair-analyzed substance use of young adults over time. European Addiction Research31(1): 60–74.
KalechsteinADDe La GarzaRIIMahoneyJJIII, et al. (2007) MDMA use and neurocognition: A meta-analytic review. Psychopharmacology189(4): 531–537.
39.
KarchSB (2011) A Historical review of MDMA. The Open Forensic Science Journal2: 20–24.
40.
KlugmanAGruzelierJ (2003) Chronic cognitive impairment in users of ‘ecstasy’ and cannabis. World Psychiatry2(3): 184–190.
41.
LawsKRKokkalisJ (2007) Ecstasy (MDMA) and memory function: A meta-analytic update. Human Psychopharmacology: Clinical and Experimental22(6): 381–388.
42.
LezakMDHowiesonDBBiglerED, et al. (2012) Neuropsychological Assessment, 5th edn. Oxford University Press.
43.
McCannUDMertlMEligulashviliV, et al. (1999) Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: A controlled study. Psychopharmacology (Berlin)143(4): 417–425.
44.
McCannUDRidenourAShahamY, et al. (1994) Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; “Ecstasy”): A controlled study in humans. Neuropsychopharmacology10(2): 129–138.
45.
McDowellDMKleberHD (1994) MDMA: Its history and pharmacology. Psychiatric Annals24(3): 127–130.
46.
MillotMSagaYDuperrierS, et al. (2020) Prior MDMA administration aggravates MPTP-induced Parkinsonism in macaque monkeys. Neurobiology of Disease134: 104643.
47.
MoherDLiberatiATetzlaffJ, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. British Medical Journal339: b2535.
48.
MontgomeryCFiskJE (2008) Ecstasy-related deficits in the updating component of executive processes. Human Psychopharmacology: Clinical and Experimental23(6): 495–511.
49.
MontgomeryCRobertsCA (2022) Neurological and cognitive alterations induced by MDMA in humans. Experimental Neurology347: 113888.
50.
MontoyaAGSorrentinoRLukasSE, et al. (2002) Long-term neuropsychiatric consequences of “ecstasy” (MDMA): A review. Harvard Review of Psychiatry10(4): 212–220.
51.
MorganMJ (1999) Memory deficits associated with recreational use of “ecstasy” (MDMA). Psychopharmacology141(1): 30–36.
52.
MorganMJMcFieLFleetwoodLH, et al. (2002) Ecstasy (MDMA): Are the psychological problems associated with its use reversed by prolonged abstinence?Psychopharmacology159(3): 294–303.
53.
MüllerFBrändleRLiechtiME, et al. (2019) Neuroimaging of chronic MDMA (“ecstasy”) effects: A meta-analysis. Neuroscience and Biobehavioral Reviews96: 10–20.
54.
NulsenCEFoxAMHammondGR (2010) Differential effects of ecstasy on short-term and working memory: A meta-analysis. Neuropsychology Review20(1): 21–32.
55.
PageMJMcKenzieJEBossuytPM, et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Revista Española de Cardiología (English Edition)74(9): 790–799.
56.
ParrottAC (2002) Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacology Biochemistry and Behaviour71(4): 837–844.
57.
ParrottAC (2004) MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: The neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology50(4): 329–335.
58.
ParrottAC (2006) MDMA in humans: Factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. Journal of Psychopharmacology20(2): 147–163.
59.
ParrottAC (2013) MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational ‘ecstasy’ users. Neuroscience and Biobehavioural Reviews37(8): 1466–1484.
60.
PotterADowneyLStoughC (2013) Cognitive function in ecstasy naive abstinent drug dependants and MDMA users. Current Drug Abuse Reviews6(1): 71–76.
61.
QuednowBBJessenFKühnK-U, et al. (2006) Memory deficits in abstinent MDMA (ecstasy) users: Neuropsychological evidence of frontal dysfunction. Journal of Psychopharmacology20(3): 373–384.
62.
ReardonS (2023) Psychedelic drug MDMA moves closer to US approval following success in PTSD trial. Nature. Epub ahead of print 14 September 2023. DOI: 10.1038/d41586-023-02886-x.
63.
RenemanLBooijJde BruinK, et al. (2001a) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. The Lancet358(9296): 1864–1869.
64.
RenemanLde WinMMvan den BrinkW, et al. (2006a) Neuroimaging findings with MDMA/ecstasy: Technical aspects, conceptual issues and future prospects. Journal of Psychopharmacology20(2): 164–175.
65.
RenemanLHabrakenJBMajoieCB, et al. (2000) MDMA (“Ecstasy”) and its association with cerebrovascular accidents: Preliminary findings. American Journal of Neuroradiology21(6): 1001–1007.
66.
RenemanLLavalayeJSchmandB, et al. (2001b) Cortical serotonin transporter density and verbal memory in individuals who stopped using 34-methylenedioxymethamphetamine (MDMA or ‘ecstasy’). Archives of General Psychiatry58(10): 901–906.
67.
RenemanLSchiltTde WinMM, et al. (2006b) Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. Journal of Psychopharmacology20(3): 389–399.
68.
RicaurteGAMartelloALKatzJL, et al. (1992) Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: Neurochemical observations. Journal of Pharmacology and Experimental Therapeutics261(2): 616–622.
69.
RobertsCAJonesAMontgomeryC (2016a) Meta-analysis of executive functioning in ecstasy/polydrug users. Psychological Medicine46(8): 1581–1596.
70.
RobertsCAJonesAMontgomeryC (2016b) Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users. Neuroscience and Biobehavioural Reviews63: 158–167.
71.
RobertsCAQuednowBBMontgomeryC, et al. (2018) MDMA and brain activity during neurocognitive performance: An overview of neuroimaging studies with abstinent ‘ecstasy’ users. Neuroscience and Biobehavioral Reviews84: 470–482.
72.
ScheffelUSzaboZMathewsWB, et al. (1998) In vivo detection of short- and long-term MDMA neurotoxicity - a positron emission tomography study in the living baboon brain. Synapse29(2): 183–192.
73.
SchenkSNewcombeD (2018) Methylenedioxymethamphetamine (MDMA) in psychiatry: Pros, cons, and suggestions. Journal of Clinical Psychopharmacology38(6): 632–638.
74.
SchiltTde WinMMLKoeterM, et al. (2007) Cognition in novice ecstasy users with minimal exposure to other drugs: A prospective cohort study. Archives of General Psychiatry64(6): 728–736.
75.
SelvarajSHoshiRBhagwagarZ, et al. (2009) Brain serotonin transporter binding in former users of MDMA (‘ecstasy’). The British Journal of Psychiatry194(4): 355–359.
76.
ShermanESTanJEHrabokM (2022) A Compendium of Neuropsychological Tests: Fundamentals of Neuropsychological Assessment and Test Reviews for Clinical Practice, 4th edn. Oxford University Press.
77.
StataCorp (2023) Stata Statistical Software, Release 17th edn. StataCorp LLC.
78.
TaurahLChandlerCSandersG (2014) Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Psychopharmacology231(4): 737–751.
79.
ThomasiusRZapletalovaPPetersenK, et al. (2006) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: The longitudinal perspective. Journal of Psychopharmacology20(2): 211–225.
UrbanNBGirgisRRTalbotPS, et al. (2012) Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: A PET study with [11C]DASB and [11C]MDL 100907. Neuropsychopharmacology37(6): 1465–1473.
82.
Van de BlaakFLDumontGJH (2022) Serotonin transporter availability, neurocognitive function and their correlation in abstinent 3,4-methylenedioxymethamphetamine users. Human Psychopharmacology: Clinical and Experimental37(1): e2811.
83.
VerbatenMN (2003) Specific memory deficits in ecstasy users? The results of a meta-analysis. Human Psychopharmacology: Clinical and Experimental18(4): 281–290.
84.
VickersM (2023) Long-term neurocognitive side effects of MDMA in recreational ecstasy users following prolonged abstinence: A systematic review [revised protocol]. Open Science Framework. Available at: https://osf.io/ewuct (accessed 30 November 2023).
85.
VrolijkRQMeashamFQuesadaA, et al. (2022) Size matters: Comparing the MDMA content and weight of ecstasy tablets submitted to European drug checking services in 2012–2021. Drugs, Habits and Social Policy23(3): 207–219.
86.
WardJHallKHaslamC (2006) Patterns of memory dysfunction in current and 2-year abstinent MDMA users. Journal of Clinical and Experimental Neuropsychology28(3): 306–324.
87.
WareingMFiskJEMontgorneryC, et al. (2007) Information processing speed in ecstasy (MDMA) users. Human Psychopharmacology: Clinical and Experimental22(2): 81–88.
88.
WareingMFiskJEMurphyP, et al. (2004a) Verbal working memory deficits in current and previous users of MDMA. Human Psychopharmacology: Clinical and Experimental19(4): 225–234.
89.
WareingMFiskJEMurphyP, et al. (2005) Visuo-spatial working memory deficits in current and former users of MDMA (‘ecstasy’). Human Psychopharmacology: Clinical and Experimental20(2): 115–123.
90.
WareingMMurphyPNFiskJE (2004b) Visuospatial memory impairments in users of MDMA (‘ecstasy’). Psychopharmacology173(3–4): 391–397.
91.
WunderliMDVonmoosMFurstM, et al. (2017) Discrete memory impairments in largely pure chronic users of MDMA. European Neuropsychopharmacology27(10): 987–999.
92.
YangJWangNLuoW, et al. (2024) The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials. Psychiatry Research339: 116043.
93.
ZakzanisKKCampbellZ (2006) Memory impairment in now abstinent MDMA users and continued users: A longitudinal follow-up. Neurology66(5): 740–741.
94.
ZakzanisKKCampbellZJovanovskiD (2007) The neuropsychology of ecstasy (MDMA) use: A quantitative review. Human Psychopharmacology: Clinical and Experimental22(7): 427–435.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
